Comprehensive decision analytical modelling in economic evaluation: A Bayesian approach

Health Economics

Volumn 13, Issue 3, 2004, Pages 203-226

  Cooper, Nicola J ^a   Sutton, Alex J ^a   Abrams, Keith R ^a   Turner, David ^a   Wailoo, Allan ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bayesian methods; Cost effectiveness analysis; Decision models; Markov chain Monte Carlo; Meta analysis

Indexed keywords

DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; NAVELBINE; OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; TAXANE DERIVATIVE; VINBLASTINE; VIRUS SIALIDASE; ZANAMIVIR;

ADVANCED CANCER; ANALYTIC METHOD; BAYES THEOREM; BREAST CANCER; CLINICAL TRIAL; COMPUTER PROGRAM; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; INFLUENZA VIRUS A; MEDICAL DECISION MAKING; MEDICAL INFORMATION; META ANALYSIS; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; RESOURCE ALLOCATION; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; STATISTICAL MODEL; SYSTEMATIC REVIEW;

EID: 1442300946     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.804     Document Type: Review

References (73)

1. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
2. Hunink M, Glasziou P, Siegel J et al. Constrained resources. Decision Making in Health and Medicine. Cambridge University Press; Cambridge; 2001; 245-304.
3. Briggs AH. Handling uncertainty in costeffectiveness models. Pharmacoeconomics 2000; 17: 479-500.
4. Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-227.
5. Lilford R, Royston G. Decision analysis in the selection, design and application of clinical and health services research. Health Serv Res Policy 1998; 3: 159-166.
6. Mugford M. Using systematic reviews for economic evaluation. In Systematic Reviews in Health Care: Meta-analysis in Context, Egger M, Davey Smith G, Altman D (eds). London: BMJ Publishing, 2001; 419-428.
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decision Making 1993; 13: 322-338.
8. Smith JQ. Decision Analysis: A Bayesian Approach. Chapman & Hall. London: 1988.
9. French S, Smith JQ. The Practice of Bayesian Analysis. Edward Arnold. London: 1997.
10. Raiffa H, Schlaifer R. Applied Statistical Decision Theory. John Wiley & Sons. Chichester: 2000.
11. Parmigiani G, Samsa G, Ancukiewicz M, Lipscomb J, Hasselblad V, Matchar DB. Assessing uncertainty in cost-effectiveness analyses. Med Decision Making 1997; 17: 390-401.
12. Matchar DB, Samsa GP, Matthews JR et al. The stroke prevention policy model: linking evidence and clinical decisions. Ann Intern Med 1997; 127: 704-711.
13. Samsa GP, Reutter RA, Parmigiani G et al. Performing cost-effectiveness analysis by integrating randomised trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. Clini Epidemiol 1999; 52: 259-271.
14. Parmigiani G. Modeling in Medical Decision Making: A Bayesian Approach. John Wiley & Sons, Ltd, Chichester: 2002.
15. Sendi PP, Craig BA, Meier G et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy 1999; 44: 811-817.
16. Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to Bayesian computing using WinBUGS. Int J Technol Assessment Health Care 2001; 17: 98-113.
17. Fryback DG, Chinnis JO, Ulvila JW. Bayesian cost-effectiveness analysis: an example using the GUSTO trial. Int J Technol Assessment Health Care 2001; 17: 83-97.
18. Cooper NJ, Abrams KR, Sutton AJ, Turner D, Lambert PC. Use of Bayesian Methods for Markov modelling in cost-effectiveness analysis: an application to taxane use in advanced breast cancer. Technical Report, Department of Epidemiology and Public Health, University of Leicester 2002; 02-02.
19. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assessment 2000; 4: 1-130.
20. Spiegelhalter DJ, Thomas A, Best NG. Win BUGS Version 1.2 User Manual. MRC Biostatistics Unit: Cambridge, 1999.
21. Lee PM. Bayesian Statistics. Arnold: London, 1997.
22. Spiegelhalter DJ. Bayesian graphical modelling: a case study in monitoring health outcomes. J R Statist Soc Ser C 1998; 47: 115-133.
23. Carlin BP, Louis TA. Bayes and Emipirical Bayes Methods for Data Analysis. Chapman & Hall: London, 2000.
24. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice: Interdisiplinary Statistics. Chapman & Hall: London, 1996.
25. Cowles MK, Carlin BP. Markov chain Monte Carlo convergence diagnostics: a comparative review. J Am Statist Assoc 1996; 91: 883-904.
26. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service research: an introduction to Bayesian methods in health technology assessment. BMJ 1999; 319: 508-512.
27. Spiegelhalter DJ, Thomas A, Best NG, Gilks WR. BUGS: Bayesian inference using Gibbs sampling version 0.50. MRC Biostatistics Unit: Cambridge, 1995.
28. Congdon P. Bayesian Statistical Modelling. John Wiley and Sons Ltd: New York, 2001.
29. Sutton AJ, Abrams KR, Jones DR, Sheldon TASF. Methods for Meta-analysis in Medical Research. John Wiley & Sons, Ltd: Chichester, England, 2000.
30. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Statist Methods Med Res 2001; 10: 277-303.
31. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Statist in Med 1995; 14: 2685-2699.
32. Prevost TC, Abrams KR, Jones DR. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer. Statist Med 2000; 19: 3359-3376.
33. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Statist Med 2001; 20: 733-753.
34. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. UK, NHS R&D HTA Programme, 1999.
35. Claxton K. Bayesian approached to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 1999; 8: 269-274.
36. Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: Application to prophylactic antibiotics use for caesarean section. Statist Methods Med Rese, 2002; 11: 491-512.
37. Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework. Technical report. University of Leicester, Department of Epidemiology and Public Health, 2002.
38. Matchar DB, Duncan P, Samsa G, et al. The stroke prevention patient outcomes research team: goals and methods. Stroke 1993; 24: 2135-2142.
39. Turner D, Wailoo A, Nicholson K, Cooper NJ, Sutton AJ, Abrams KR. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment Report 2002.
40. British Medical Association & Royal Pharmaceutical Society of Great Britain. British National Formulary. http://www.bnf.org/ 2002; 43.
41. Deeks JJ, Altman DG. Effect measures for meta-analysis of trials with binary outcomes. In Systematic reviews in health care: Meta-analysis in context, Egger M, Davey Smith G, Altman DG (eds). BMJ Publishing Group. London, 2001; 313-335.
42. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? (abstract). 22nd Annual Conference of the International Society for Clinical Biostatistics (ISCB), Stockholm, Sweden, 2001.
43. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Statist Med 1997; 16: 2741-2758.
44. Sharp SJ,. Thompson SG. Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. Statist Med 2000; 19: 3251-3274.
45. van Houwelingen HC, Zwinderman K, Stijnen T. A bivariate approach to meta-analysis. Statist Med 1993; 12: 2272-2284.
46. DeGroot MH. Sampling distributions of estimators. Probability and Statistics. Addison-Wesley Publishing Company: United States, 1986, 381-436.
47. Netten J, Curtis J. Unit costs of health and social care 2000. Personal Social Services Research Unit (PSSRU) 2001.
48. Christiansen CL, Morris CN. Hierarchical poisson regression modeling. J Am Statist Assoc 1997; 92: 618-632.
49. Natarajan R, Kass RE. Reference Bayesian methods for generalised linear mixed models. J Am Statist Assoc 2000; 95: 227-237.
50. Daniels MJ. A prior for the variance components in hierarchical models. Can J Statist 1999; 27: 569-580.
51. Spiegelhalter DJ. Bayesian methods for cluster randomised trials with continuous responses. Statist Med 2001; 20: 435-452.
52. DuMouchel W, Normand S. Computer-modeling and graphical strategies for meta-analysis. In Meta-analysis in Medicine and Health Policy, Stangl DK, Berry DA (eds). Marcel Dekker: 2000, New York, 127-178.
53. Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statist Med 1996; 15: 2733-2749.
54. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of Docetaxel versus Doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
55. BROWN RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-Cancer Drugs 1998; 9: 899-907.
56. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary, 1999.
57. Lister-Sharp D, McDonagh, M, Khan, KS, Kleijnen J. A systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technology Assessment: NHS R&D HTA Programme, 2000.
58. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of Docetaxel versus Mitomycin plus Vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-1424.
59. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by Scandinavian breast cancer group. Eur J Cancer 1999; 35: 1194-1201.
60. Bonneterre J, Roche H, Monnier A et al. Taxotere (TXT) versus 5-fluorouracil+navelbine (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 1997; 16: A564.
61. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002; 11: 233-248.
62. Bauer C, Elie K, Spence L, Stern L. Hong Kong Influenza in a neonatal unit. JAMA 1973; 223: 1233-1235.
63. Miller DK, Homan SM. Determining transition probabilities: Confusion and suggestions. Med Decision Making 1994; 14: 52-58.
64. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomic 1996; 9: 8-22.
65. Gore SM. Biostatistics and the Medical Research Council. Med Res Council News 1987; 19-20.
66. Abrams KR, Ashby D, Errington RD. Simple Bayesian analysis of a clinical trial - a tutorial. Controlled Clini Trials 1994; 14: 255-260.
67. Parmar MK, Griffiths GO, Spiegelhalter DJ, Souhami RL, Altman DG, van der Scheuren E. CHART steering committee. Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet 2001; 358: 375-381.
68. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
69. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-364.
70. Claxton K, Thompson K. A dynamic programming approach to the efficient design of clinical trials. J Health Econ 2001; 20: 797-822.
71. Ades AE, Clifle S. Markov Chain Monte Carlo estimation of a multiparameter decision model: Consistency of evidence and the accurate assessment of uncertainty. Med Decision Making 2002; 22: 359-371.
72. O'Brien MER, Leonard RC, Barrett-Lee PJ, Eggleton PH, Bizzari JP. Docetaxel in the community setting: an analysis of 377 breast cancer patients treatment with docetaxel (Taxotere) in the UK. Ann Oncol 1999; 10: 205-210.
73. Bontenbal M, Andersson M, Wildiers J et al. Doxorubicin vs epirubicin, report of second-line randomized phase II/III study in advanced breast cancer. Br J Cancer 1998; 77: 2257-2263.